GID BIO Blog
Read Updates from GID BIO.
San Antonio Business Journal features GID BIO and pivotal/Phase III trial principal investigator, Dr. Jaime Garza: “On the forefront of new cell therapy research, an Alamo City surgeon has a key role in moving new medical technology to market”
GID BIO completed a pivotal Phase IIb clinical trial with an FDA-compliant study design using autologous stromal cells in the
GID BIO begins pivotal/Phase III clinical trial patient enrollment process at Texas Center for Cell Therapy and Research in San Antonio
This summer, the FDA cleared our stromal-vascular-fraction cellular therapy for a pivotal/Phase III clinical trial to test its safety and
Denver Business Journal features GID BIO: “Colorado biotech firm’s new cell therapy could eliminate the need for knee replacements”
As the total number of confirmed COVID-19 cases surpasses five million in the US, companies across the country are researching
GID BIO welcomes business titan, Roy J. Bostock as new board chair
Our team announced that Roy J. Bostock, a global business leader with decades of experience, has been elected as the
Physicians: advancing the future of evidence-based cellular therapy could increase quality of life for 14 million US adults suffering from knee osteoarthritis
Over the past three decades cardiothoracic procedures have significantly shifted to minimally invasive techniques with new technology, training of physicians
Leaders come together for the first time to advance the field of cellular therapy and its treatment of pain and function associated with knee osteoarthritis
A first-of-its kind meeting brought leaders from eight orthopedic, sports medicine, pain management and regenerative medicine advocacy organizations together to
Device and cellular therapy could lead to a major development in the treatment of pain and function associated with knee osteoarthritis for 14 million US adults
Individuals who overuse their joints, such as athletes, military members and people working physically demanding jobs are at a high
GID BIO aims to make treatment for pain and function associated with knee osteoarthritis accessible to millions with a single-use device and point-of-care therapy
Osteoarthritis (OA) of the knee is a painful disease that impacts 14 million U.S. adults. With no surgical or pharmaceutical treatment
